The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that could have broad consequences for generic drug makers and so-called "skinny ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. As if news outlets didn’t bombard you with ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Join us Jan. 14 for a virtual discussion about our Rx ...

PHOENIX — With flu cases rising overseas in countries like the United Kingdom and a new variant identified in Japan, experts warn that the United States could face an earlier flu season this year.

The generic product is now available nationwide in strengths of 0.3mg, 0.45mg, 0.625mg, 0.9mg, and 1.25mg. The Food and Drug Administration (FDA) has approved the first generic version of Premarin ® ...

Pazdur, a 26-year veteran of the FDA, will take over as the director of the Center for Drug Evaluation and Research (CDER), the FDA’s largest unit. A cancer specialist, Pazdur has previously held ...

FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, April 22, 2025. (AP Photo/Jose Luis Magana, File) (Jose Luis Magana) Dr. Richard Pazdur, ...

Dr. Richard Pazdur, who has been the F.D.A.’s top cancer drug regulator, represents a stabilizing choice for an agency reeling under staff cuts and low morale. By Christina Jewett and Rebecca Robbins ...

Dear Toni: I signed up for a supplemental Medicare Plan G and a Medicare Part D prescription drug plan, both of which started in January 2021. These two plans have served me well. I just received ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...